Must begetting close to some news on this.
https://www.ema.europa.eu/en/docume...n-agreed-paediatric-investigation-plan_en.pdf
Page 7
Study 1
A randomised, double blind, multi-centre, placebo-controlled study to evaluate the safety and efficacy of methoxyflurane for the treatment of acute pain in children from 12 to less than 18 years of age (and in adults) presenting to an Emergency Department with minor trauma (MEOF-001).
Study 2
A randomised, double-blind, multi-centre, placebo controlled study to evaluate safety and efficacy of methoxyflurane for the treatment of acute pain in children and adolescents from 6 to less than 18 years of age presenting to an Emergency Department with minor trauma (MEOF-002).
Date of completion of the paediatric investigation plan: By July 2021
Another Positive Study, page-12
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.005(1.15%) |
Mkt cap ! $49.56M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 45.0¢ | 43.0¢ | $72.64K | 164.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3355 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 15645 | 1 |
View Market Depth
| Last trade - 15.56pm 13/09/2024 (20 minute delay) ? |
| MVP (ASX) Chart |